Incyte logo

INCY - Incyte News Story

$81.28 0.0  0.0%

Last Trade - 05/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £12.86bn
Enterprise Value £11.47bn
Revenue £1.94bn
Position in Universe 648th / 6849

BUZZ-BriaCell Therapeutics: Jumps as lead drug helps control disease across trials

Mon 12th April, 2021 1:23pm
** Shares of drug developer BriaCell Therapeutics Corp
 BCTX.O  jump 14% to $5.92 premarket
    ** Co presents data from studies of its lead drug candidate
Bria-IMT at American Association for Cancer Research (AACR)
Annual Meeting 2021 
    ** Data shows therapy helped in disease control in advanced
breast cancer patients, co says  urn:newsml:reuters.com:*:nGNXWmX1x
    ** Patients with low or undetectable levels of circulating
cancer cells were more likely to benefit from therapy - BCTX
    ** Patients were treated with either Bria-IMT alone or in
combination with Merck & Co's  MRK.N  Keytruda and Incyte Corp's
 INCY.O  retifanlimab
    ** Stock down 48.3% in last 12 months

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.